Bio Path Holdings Inc (BPTH)

[wordlender]

Although I am also frustrated and I agree with much of what others are saying, let me try to post a counter-balance to the doom and gloom on this board. First, results have been great - the science works. We all know that already.

PStates said "testing has evidently stopped." Unless I missed something, his statement is simply not true. Go here to see for yourselves:

https://clinicaltrials.gov/ct2/show/NCT02781883?term=Bio-Path&rank=2

Notice that assessment of efficacy takes 180 days. Also, there are numerous inclusion and exclusion criteria, which might be part of why it takes so long to complete these trials. We need frail elderly people with cancer who don't die too quick. That can be hard to come by - this population has co-morbidity issues.

They are dosing patients and will eventually have results that can be released to the public. People should also know that there is a certain degree of separation between the company and the clinic. These trials are independent from the company - that way they can be trusted. That also means the company does not have access to a lot of the information while the trials are ongoing. I know there have been delays, but we need to be patient for a little longer. The end of Phase II is expected in Dec. 2018 with preliminary data after 19 patients fully dosed and assessed (180 days after first dose). First patient was dosed at the beginning of November 2016 - almost 180 days ago - based on press release issued 11.02.2016.

We have orphan drug designation from FDA and EU, which means, currently, there is no competition.

A look at institutional investors shows that University of Texas and other top shareholders are holding steady. http://finance.yahoo.com/quote/BPTH/holders?p=BPTH


One more round of financing should get us to a point in the clinical trials where we can apply for accelerated approval or have bargaining power to cut a deal with a larger biotech company (or both). I believe that upcoming dilution is already priced into the stock, and at this point, securing a new round of financing should be viewed as a positive as it will show that investors are still seeing potential here. We'll see how this plays out in about six months when capital is needed.

I think in six months this stock will be double where it is now, and in 18 - 24 months we will hit a new all-time high. When the data from those 19 patients comes out, investors will come in speculating that BPTH will get accelerated approval or a partnership (or both). I bet a partnership will be conditioned on hiring a new CEO.

Also, let's give the new guy a chance to move things in the right direction.

That's all I got for a counter-balance.